NT5E

Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, August 5, 2021
Company, Investor, Cystic Fibrosis Foundation, Research, NT5E, Investment, Webcast, U.S. Securities and Exchange Commission, Asco, American Society of Clinical Oncology, Mutation, Development, Private Securities Litigation Reform Act, Risk, Broad, Large-cell lung carcinoma, Arginase, Consortium, PFS, Patient, Security (finance), Conference, Therapy, Commercialization, Biomarker, Society, Pemetrexed, Cancer, CALA, Carboplatin, NFE2L2, Data, Non-small-cell lung carcinoma, Cystic fibrosis, SAN, Pembrolizumab, Neoplasm, Adult, ID, Cabozantinib, Nasdaq, Doctor of Philosophy, KEAP1, Safety, RCC, Annual general meeting, Â, GLOBE, Cryptocurrency, Pharmaceutical industry, Tutoring

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Calithera anticipates releasing interim data from the KEAPSAKE trial in the fourth quarter of 2021.
  • Revenue was $3.0 million for the three months ended June 30, 2021 and represents revenue recognized in the second quarter from the companys license agreement with Antengene.
  • Research and development expenses for the second quarter 2021 were $12.8million, compared to $15.6million in the same period prior year.
  • General and administrative expenses for the second quarter 2021 were $4.5million, compared to $5.1million in the same period prior year.

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights

Retrieved on: 
Thursday, August 5, 2021
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Lung, Cancer, RDE, Chief executive officer, Research, List of life sciences, NT5E, Investment, Orr, Population, Pancreatic cancer, PFS, IND, Partnership, TKI, Autumn, Patient, Board, Docetaxel, Data, Non-small-cell lung carcinoma, New York Stock Exchange, Prostate, Prostate cancer, AstraZeneca, MCRPC, D, NP, Board of directors, Safety, Colon, Conference, Pharmaceutical industry, Medical imaging

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.
  • Based on this dataset, Arcus and Gilead will continue preparations for additional Phase 3 studies of dom-based combinations.
  • Results from the interim analysis for ARC-7 are expected to be submitted later this year for a presentation in 4Q21 or in 1H22.
  • Management will host a conference call today, August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights.

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

Retrieved on: 
Thursday, August 5, 2021
Company, GlaxoSmithKline, Stomach, NT5E, U.S. Securities and Exchange Commission, Forward-looking statement, Asco, Large-cell lung carcinoma, American Society of Clinical Oncology, Novartis, Pancreatic cancer, Hepatocellular carcinoma, Annual report, Roche, Security (finance), Private Securities Litigation Reform Act, Bevacizumab, IND, ENTPD1, GSK, Patient, PVRIG, COVID-19, Drug discovery, Interleukin 27, Tumor microenvironment, Society, Non-small-cell lung carcinoma, Phase 1, Risk, HCC, CCR8 (gene), Renal cell carcinoma, Research, R, RCC, Annual general meeting, G&A, Corporation, GLOBE, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2021, and provided an update on anticipated corporate milestones.

Key Points: 
  • The second quarter marked a major milestone for Surface, with SRF388 monotherapy eliciting the first-ever clinical response from a therapeutic targeting the IL-27 pathway.
  • On June 4, 2021, Surface presented preliminary data from the ongoing Phase 1 study of SRF388, an anti-IL-27 antibody, at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
  • R&D expenses included $0.9 million in stock-based compensation expense for the second quarter ended June30, 2021.
  • G&A expenses included $1.4 million in stock-based compensation expense for the second quarter ended June30, 2021.

Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Nursing, Cancer, List of life sciences, NT5E, Webcast, Lymphatic system, Non-small-cell lung carcinoma, New York Stock Exchange, Prostate, AstraZeneca, Gemcitabine, Conference, Arcus, Disease, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.
  • A live audio webcast of the presentation will be available by visiting the Investors section of the Arcus website at www.arcusbio.com .
  • A replay of the webcast will be available for at least two weeks following the live event.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Retrieved on: 
Thursday, July 15, 2021
Clinical medicine, Medical specialties, Medicine, Clusters of differentiation, Immunology, NT5E, Immune system, Monoclonal antibody, Immunotherapy, Tumor microenvironment, Cancer immunotherapy, ENTPD1

The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.

Key Points: 
  • The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.
  • Mupadolimab (formerly CPI-006) is a humanized anti-CD73 antibody that binds to various immune cells including most B cells.
  • Binding to CD73 inhibits production of immunosuppressive adenosine in the tumor microenvironment, similar to other recently described anti-CD73 antibodies.
  • In addition, Corvus has published results from the initial cohorts of its Phase 1 COVID-19 study and pre-clinical data characterizing the novel immunotherapy approach with mupadolimab online at medRxiv.org.

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

Retrieved on: 
Monday, June 28, 2021
Clinical medicine, Medicine, Medical specialties, Clusters of differentiation, Antineoplastic drugs, Oncology, NT5E, Adenosine, Chemotherapy

ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.

Key Points: 
  • ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
  • In preclinical studies, ORIC-533 has demonstrated higher potency within a high AMP environment compared to all CD73 and adenosine receptor inhibitors against which it was compared.
  • ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
  • ORIC-533 has demonstrated greater potency in preclinical studies compared to an antibody approach, other small molecule CD73 inhibitors and inhibitors of adenosine receptors.

I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab

Retrieved on: 
Wednesday, June 2, 2021
Clusters of differentiation, Branches of biology, Medical specialties, Clinical medicine, NT5E, Atezolizumab, Adenosine, Stromal cell

ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.

Key Points: 
  • ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.
  • ET via Zoom:
    Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies.
  • Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Retrieved on: 
Monday, May 17, 2021
Drug discovery, Branches of biology, NT5E, Small molecule, Biology, Life sciences

"CB-708is a highly differentiated oral small molecule CD73 inhibitor with best-in-class potential due to its oral-bioavailability and high potency.

Key Points: 
  • "CB-708is a highly differentiated oral small molecule CD73 inhibitor with best-in-class potential due to its oral-bioavailability and high potency.
  • "Antengene brings significant enthusiasm and proven global capabilities to the development and future commercialization of CB-708, a potential best-in-class oral small molecule CD73 inhibitor.
  • Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world.
  • Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.

Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

Retrieved on: 
Monday, May 17, 2021
Branches of biology, NT5E, Small molecule, Biology, Life sciences

\xe2\x80\x9cAntengene brings significant enthusiasm and proven global capabilities to the development and future commercialization of CB-708, a potential best-in-class oral small molecule CD73 inhibitor.

Key Points: 
  • \xe2\x80\x9cAntengene brings significant enthusiasm and proven global capabilities to the development and future commercialization of CB-708, a potential best-in-class oral small molecule CD73 inhibitor.
  • Additionally, Calithera is eligible to receive tiered royalties on sales of the licensed product up to low double-digits.
  • Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world.
  • Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

Retrieved on: 
Wednesday, May 5, 2021
Clusters of differentiation, NT5E, Clinical medicine, Cancer immunotherapy, Medicine, Immunotherapy, Humanized antibody, Monoclonal antibodies

Before purchasing shares, prospective investors should read the prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein.

Key Points: 
  • Before purchasing shares, prospective investors should read the prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein.
  • Prospective investors may obtain these documents for free by visiting EDGAR on the SEC\xe2\x80\x99s website at www.sec.gov.
  • Corvus\xe2\x80\x99 lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies.
  • Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.